Host: The Japanese Society of Toxicology
Name : The 47th Annual Meeting of the Japanese Society of Toxicology
Date : 2020 -
More than three years have passed since SEND became mandatory by the US FDA in December 2016. Some Japanese pharmaceutical companies, especially those who develop medicines globally, have already implemented SEND, and some have decided to wait for the conclusion of the introduction of SEND to Japan.
In this presentation, we would like to explain the current situation surrounding SEND from the viewpoint of pharmaceutical manufacturers, taking into account such situations, and to summarize the issues to be considered depending on the differences in companies’ positions.
